Simulations Plus, Inc. (NASDAQ:SLP) Given Average Rating of “Buy” by Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $51.40.

A number of equities analysts have issued reports on the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Stephens assumed coverage on Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price on the stock. Finally, StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP opened at $31.92 on Friday. The business has a fifty day moving average of $30.79 and a 200-day moving average of $36.55. The firm has a market cap of $640.54 million, a PE ratio of 65.14 and a beta of 0.76. Simulations Plus has a twelve month low of $27.07 and a twelve month high of $51.22.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the company earned $0.18 earnings per share. The company’s revenue was up 19.9% on a year-over-year basis. On average, analysts anticipate that Simulations Plus will post 1.1 EPS for the current fiscal year.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $27.66, for a total value of $553,200.00. Following the completion of the sale, the director now directly owns 3,462,584 shares in the company, valued at $95,775,073.44. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 60,750 shares of company stock worth $1,837,255 in the last ninety days. 20.90% of the stock is owned by company insiders.

Institutional Trading of Simulations Plus

A number of institutional investors have recently modified their holdings of SLP. Deerfield Management Company L.P. Series C acquired a new stake in Simulations Plus in the second quarter valued at about $811,000. Royce & Associates LP boosted its stake in Simulations Plus by 28.8% in the third quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock valued at $7,602,000 after buying an additional 53,092 shares in the last quarter. US Bancorp DE boosted its stake in Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after buying an additional 1,343 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after buying an additional 32,002 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Simulations Plus in the third quarter valued at about $59,000. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.